FDA Clearance Tracker · K170901
ALBUMIN, ALKALINE PHOSPHATASE (ALP)-AMP, GLUCOSE-HEXOKINASE, BA400
Last checked: Nov 19, 2026Latest source record: Apr 13, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Apr 13, 2018
Substantially Equivalent
Time to decision
382 days
Received Mar 27, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K170901
- Device name
- ALBUMIN, ALKALINE PHOSPHATASE (ALP)-AMP, GLUCOSE-HEXOKINASE, BA400
- Applicant
- Biosystems S.A.
- Applicant location
- Barcelona, ES
- Received
- Mar 27, 2017
- Decided
- Apr 13, 2018
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- Bromcresol Green Dye-Binding, Albumin (CIX)
- Device class
- Class II
- Regulation
- 21 CFR 862.1035
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code CIX. The earliest in FDA's data is K760355, decided Oct 5, 1976.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K170901
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Biosystems S.A.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K192730 · Decided Sep 9, 2020 · 348 days after receipt
Device type: Titrimetric With Edta And Indicator, Calcium (CHW) · Laboratory Medicine & Pathology
- Transferrin510(k)
K190495 · Decided Mar 16, 2020 · 382 days after receipt
Device type: Transferrin, Antigen, Antiserum, Control (DDG) · Laboratory Medicine & Pathology
- alpha-AMYLASE DIRECT, alpha-AMYLASE EPS, alpha-AMYLASE PANCREATIC, BILIRUBIN DIRECT, BILIRUBIN TOTAL510(k)
K182474 · Decided May 2, 2019 · 234 days after receipt
Device type: Catalytic Methods, Amylase (JFJ) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.